86901
document
Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT .
86902
Intervention_Pharmacological
Iobitridol 300
86903
Intervention_Pharmacological
iopromide 300 -- a
86904
Intervention_Pharmacological
iobitriodol 300 mg I/ml and iopromide 300 mg I/ml
86905
Intervention_Pharmacological
iobitridol
86906
Intervention_Pharmacological
iopromide
86907
Intervention_Pharmacological
Iobitridol
86908
Outcome_Other
onset
86909
Outcome_Adverse-effects
adverse reaction
86910
Outcome_Other
imaging quality
86911
Outcome_Adverse-effects
side effects
86912
Outcome_Other
excellent image quality
86913
Outcome_Adverse-effects
low rate of side effects
86914
Outcome_Other
safe
86915
Outcome_Other
effective nonionic contrast agent
86916
Participant_Condition
total body CT.